ResMed (NYSE: RMD) reported Q1 EPS of $0.62, $0.02 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $465.4 million versus the consensus estimate of $474.73 million.

For earnings history and earnings-related data on ResMed (RMD) click here.